Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 2/20 | 0.37 |
| ▸ | METAP2 | P50579 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14363014 | 0.85 | BCHE (0.38) | BCHEMEN1KMT2ASLC6A2POLB | |
| SCHEMBL402930 | 0.84 | BCHE (0.41) | BCHEMEN1KMT2ASLC6A2POLB | |
| SCHEMBL19980839 | 0.82 | BCHE (0.47) | BCHESLC6A2KLK7KLK5 | |
| SCHEMBL403846 | 0.81 | TDP1 (0.48) | BCHEMEN1KMT2ASLC6A2OPRM1 | |
| SCHEMBL19976424 | 0.78 | TSHR (0.51) | BCHEKMT2ASLC6A2POLBGAA | |
| SCHEMBL402639 | 0.77 | SLC6A2 (0.60) | BCHESLC6A2POLBGAAMETAP2 | |
| SCHEMBL22582956 | 0.76 | BCHE (0.45) | BCHESLC6A2KLK7KLK5 | |
| SCHEMBL22965651 | 0.76 | BCHE (0.48) | BCHEPOLBGAAMETAP2 | |
| SCHEMBL21339695 | 0.74 | BCHE (0.48) | BCHEKMT2ASLC6A2POLBGAA | |
| SCHEMBL30040993 | 0.74 | ALDH1A1 (0.47) | BCHEKMT2ASLC6A2POLBKLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | HPSE, HAAO, HEXD | BCHE 1419/4885MEN1 3276/4885KMT2A 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.